NEWRON PHARMACEUT. EO-20
Save
175.13M
Market cap
–
Current P/E
12.15x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Newron Pharmaceuticals S.p. A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea.
Similar securities
Based on sector and market capitalization
Report issue